Litigation Details for Novartis Pharmaceuticals Corporation v. Mylan Inc. (N.D.W. Va. 2014)

Novartis Pharmaceuticals Corporation v. Mylan Inc. (N.D.W. Va. 2014)

Docket		Date Filed	2014-06-26
Court	District Court, N.D. West Virginia	Date Terminated	2015-10-30
Cause	35:271 Patent Infringement	Assigned To	Irene Patricia Murphy Keeley
Jury Demand	None	Referred To
Patents	6,465,504; 6,596,750
Link to Docket	External link to docket

Details for Novartis Pharmaceuticals Corporation v. Mylan Inc. (N.D.W. Va. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
0000-00-00	36		claims of U.S. Patent Nos. 6,465,504 (“the ’504 Patent”) and 6,596,750 (“the ’750 Patent”) are invalid…Declaratory Judgment of Non-Infringement of the ’504 Patent) -2-…that Mylan is liable for infringement of the ’504 Patent. Novartis denies any and all remaining allegations…Declaratory Judgment of Non-Infringement of the ’750 Patent) 28. Novartis hereby incorporates the…that Mylan is liable for infringement of the ’750 Patent. Novartis denies any and all remaining allegations	External link to document
0000-00-00	38		3 Patent No. 6,465,504 (“the ‘504 Patent”), issued on October 15, 2002, and Patent No. 6,596,…that the patent has expired; (3) the date on which the patent will expire; or, (4) that the patent is invalid…judgment that Mylan infringed its patents; 2) a judgment that the patents are valid and enforceable; 3) …four conditions regarding the patent status of the brand drug: (1) that patent information for the brand …any infringement of Novartis’ patents, and countering that the patents are invalid (Dkt. No. 31 at 17	External link to document
0000-00-00	46		claims of Novartis’s U.S. Patent No. 6,465,504 (the “’504 patent”) is invalid. Discovery will…and validity/invalidity of the patents-in-suit. The patents-in-suit have already been litigated… more claims of Novartis’s U.S. Patent No. 6,596,750 (the “’750 Patent”) is invalid. Discovery…infringes one or more claims of the ’504 patent or ’750 patent literally or under the doctrine… 2015, Novartis shall produce the patents-in-suit and associated prosecution	External link to document
0000-00-00	65		Number(s) 6,465,504; 6,596,750. (lih) (Entered: 03/22/2012) 03/21/2012 … Nature of Suit: 830 Patent Cause: 35:271 Patent Infringement … 4 Report to the Commissioner of Patents and Trademarks for Patent/Trademark …informally, or directly or indirectly, in any patent prosecution directed to any deferasirox drug product…party, in the preparation or prosecution of any patent application directed to EXJADE® described in	External link to document
0000-00-00	66		infringe Plaintiffs’ patents—U.S. Patent No. 6,465,504 (the ’504 patent) and U.S. Patent No. 6,596,750 (the…’750 patent) (collectively, “the asserted patents”). In addition to owning the asserted patents, Plaintiffs…642 II. BACKGROUND This is a patent infringement case relating to Mylan Pharmaceuticals…caused by repeated blood transfusions.” The ’504 patent is generally directed to a compound or composition…composition including deferasirox, and the ’750 patent is generally directed to a method of treating certain	External link to document
0000-00-00	75		2 Patent No. 6,465,504 (“the ‘504 Patent”), issued on October 15, 2002, and Patent No. 6,596,…judgment that Mylan infringed its patents; 2) a judgment that the patents are valid and enforceable; 3) …any infringement of Novartis’ patents, and countering that the patents are invalid (Dkt. No. 31 at 17…does not infringe Novartis’ patents, a declaration that the patents are invalid, dismissal of …“Novartis”), filed a complaint for patent infringement against defendants	External link to document